Best Life Sciences Companies in Denmark
The 493 best Life Sciences companies in Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Symphogen.
Denmark's Life Sciences sector draws serious capital, and this directory ranks 493 tracked companies by disclosed equity funding and recent momentum — because that's where the real signal lives.
$4.9B in total disclosed funding across the cohort. Two unicorns. Hemab leads the top-funded names at $190M raised, with Bavarian Nordic close behind at $185M and Adcendo adding $113M. Those figures aren't projections; they're validated filings. The global life sciences market is priced around $167.8B with a 10.2% CAGR, so Denmark's concentrated funding pool punches well above its geographic weight. Novo Holdings and BioInnovation Institute anchor the most active investor list, which tells you something about the institutional depth behind these rounds. And if you're wondering whether digital health is compounding the story, a recent IPO filing from Sai Life Sciences underscores how aggressively capital markets are chasing this sector globally right now. I'd watch the SNIPR Biome and Kvantify trajectories closely. The funding momentum here is real, the investor roster is credible, and the scale is already measurable.
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Denmark
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Symphogen Developer of recombinant antibody for treatment of cancers | $671M | 84 mo ago | 103 103 → 219 (+113%) · sector median +71% | Martin Olin CEO | — | 581 patents Immune checkpoint antibody therapeutics targeting PD‑1, TIM‑3, and LAG‑3 | 4 job openings |
| 2 | LEO Pharma 🦄 Developer of drugs for treating dermatology diseases | $561M | 50 mo ago | 77 | Christophe Bourdon CEO | 5 signals ▼38% Earnings · Leadership · Contracts | 1,266 patents Patents concentrated in chemistry & materials | — |
| 3 | Minervax Developer of vaccines against life-threatening infections in newborns | $197M | 32 mo ago | 7 | Per Fischer CEO | — | — | — |
| 4 | Hemab 🦄 Developer of preventative treatments for rare bleeding and thrombotic disorders | $190M | 7 mo ago | 10 | — | 5 signals IPO · Funding | — | — |
| 5 | Bavarian Nordic Developer of therapeutic vaccines against cancer and infectious diseases | $185M | 17 mo ago | 35 | — | 14 signals ▼58% Earnings · Buyback · Leadership | 1,104 patents Patents concentrated in chemistry & materials | — |
| 6 | IO Biotech Developer of vaccine for the treatment of cancer | $175M | 34 mo ago | 15 15 → 36 (+140%) · sector median +71% | Mai-Britt Zocca CEO and Founder | 5 signals ▼55% Leadership · Announcements · Earnings | 2 patents Therapeutic vaccines and osteoprotegerin ligand inhibition for bone disease treatment | — |
| 7 | NMD Pharma Developper of Ion-channel targeted drugs for treating neuromuscular synaptic disorders | $174M | 31 mo ago | 26 | — | — | 165 patents Small‑molecule therapeutics targeting chloride channels for neuromuscular diseases | 1 job opening |
| 8 | Galecto Biotech Developer of galectin modulators for treating idiopathic pulmonary fibrosis | $160M | 68 mo ago | 29 | Hans Schambye President & CEO | 8 signals ▲100% Earnings · M&A · IPO | 184 patents Small-molecule galactoside inhibitors targeting galectin proteins for therapeutic use | — |
| 9 | Adcendo Developer of antibody-drug conjugates for the treatment of cancer | $113M | 2 mo ago | 23 | Niels Behrendt Co-Founder | — | — | — |
| 10 | Santaris Pharma Developer of RNA-targeted therapies for infectious and metabolic diseases | $104M | 168 mo ago | 60 | Peter Sondermann Founder & CEO | — | 516 patents Therapeutic antisense oligonucleotides for TNF receptor modulation and microRNA inhibition | — |
| 11 | Muna Therapeutics Developer of small-molecule therapeutics for neurodegenerative diseases | $102M | 44 mo ago | 16 | Rita Balice-Gordon CEO | — | 35 patents Immunomodulatory small molecules targeting TREM2 and Kv1.3 for neuroinflammation therapy | — |
| 12 | Antag Therapeutics Developer of peptide-based therapies for obesity and cardiometabolic disorders | $87M | 18 mo ago | — | Alexander Sparre-Ulrich Co-Founder & COO | — | 39 patents Design and optimization of GIP peptide analogs for metabolic/obesity therapeutics | — |
| 13 | Blue Ocean Robotics Manufacturer of professional service robots | $81M | 53 mo ago | 303 | John Ostergaard Co-Founder & CTO | — | 59 patents Autonomous mobile robots for healthcare disinfection, remote control, sensor validation, and patient lifting. | 2 job openings |
| 14 | Acesion Pharma Developer of drugs for treating atrial fibrillation | $70M | 32 mo ago | 7 | Morten Grunnet Co-Founder & CSO | — | 30 patents Patents concentrated in chemistry & materials | — |
| 15 | MedTrace Developer of molecular imaging tools for quantifying blood flow | $66M | 32 mo ago | 17 | Peter Larsen Co-Founder & CTO | — | 19 patents Safe preparation and infusion systems for short-lived diagnostic radiopharmaceuticals | — |
| 16 | Novozymes Developer of biosolutions and enzymes for multiple industries and applications of biotechnology | $61M | 60 mo ago | 6,781 | — | — | 11,898 patents Industrial enzyme biotechnology for food, feed, detergents, and bio‑processes | — |
| 17 | Orphazyme ApS Developer of therapeutics for the treatment of rare and genetic diseases | $59M | 69 mo ago | 141 | Anders Vadsholt CEO | — | 70 patents Small-molecule Hsp70 inducers and extended-release formulations for protein‑misfolding therapies | — |
| 18 | SNIPR Biome Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely | $54M | 10 mo ago | 48 48 → 46 (-4%) · sector median +71% | Morten Sommer Co-Founder | 3 signals Funding · Capital raise | 142 patents Engineered microbial therapeutics and delivery vectors for infection control and stressed cell targeting | 4 job openings |
| 19 | Reapplix Developer of patch system for wound healing | $52M | 71 mo ago | 24 24 → 41 (+71%) · sector median +71% | Rasmus Lundquist Co-Founder & Co-Owner | — | 5 patents Blood-derived hemostatic and anti-adhesion biomaterials for surgical wound management | 1 expansion |
| 20 | Allarity Therapeutics Developer of therapeutic solutions for cancer treatments | $50M | 37 mo ago | 7 | Thomas Jensen Founder | 3 signals ▼84% Earnings · Funding | 21 patents Predictive oncology biomarkers for chemotherapy response, especially ixabepilone companion diagnostics. | — |
| 21 | Evosep Developer of solutions for clinical proteomics | $49M | 41 mo ago | 20 | Ole Vorm Founder & Director | — | — | 2 job openings |
| 22 | Draupnir Developer of small molecule therapeutics targeting extracellular and membrane-bound proteins | $46M | 23 mo ago | 18 | Andrew Hotchkiss Chief Executive Officer | — | — | — |
| 23 | BACTOLIFE Developer of biological solutions to reduce bacterial gastrointestinal infections | $44M | 5 mo ago | 22 | Sandra Thrane Co-Founder & CSO | — | 14 patents Engineered single-domain antibody fusion proteins targeting gastrointestinal pathogens | 1 job opening |
| 24 | CathVision Provider and developer of an AI-based cardiac ablation therapy software and device | $36M | 35 mo ago | 18 18 → 40 (+122%) · sector median +71% | Rune Orndrup Co-Founder | — | — | 1 launch · 1 expansion |
| 25 | Orbis Medicines Provider of drug discovery platform to develop multiple therapeutics | $33M | 17 mo ago | 8 | Sevan Habeshian Co-Founder | — | — | — |
| 26 | Synklino Developer of drugs for the treatment of chronic viral infections | $32M | 48 mo ago | 5 | Thomas Kledal CEO & Co-Founder | — | 6 patents Ex vivo organ preservation and perfusion compositions for transplant readiness | 1 award |
| 27 | Unibio Pioneering planet-friendly protein production through advanced fermentation for animal and human nutrition | $30M | 38 mo ago | 59 59 → 142 (+141%) · sector median +71% | — | — | 109 patents Optimizing microbial fermentation for single‑cell protein and biomass production | 1 partnership |
| 28 | ViroGates Developer of biomarkers and diagnostic kits | $28M | 46 mo ago | 9 | Jakob Knudsen CEO | — | 11 patents Risk assessment and diagnostic methods for SARS‑CoV‑2 infection using medical testing devices | 1 partnership |
| 29 | Hoba Therapeutics Developer of therapeutics for the treatment of neuropathic pain and hearing disorders | $27M | 30 mo ago | 3 | Kenneth Petersen Founder | — | 22 patents Analgesic therapeutics for nociceptive and chemotherapy‑induced neuropathic pain | — |
| 30 | UNION Therapeutics Developer of small molecule antibiotic drugs for treating bacterial infections | $25M | 47 mo ago | 36 | Rasmus Toft-Kehler Co-Founder | — | 165 patents Dermatology-focused PDE4 inhibitor formulations for inflammatory skin disease treatment | — |
| 31 | Biosyntia Developing biocatalysts using synthetic biology and metabolic engineering technology | $23M | 47 mo ago | 19 19 → 22 (+16%) · sector median +71% | Hans Genee Co-Founder and CSO | — | — | 1 award |
| 32 | NEUmiRNA Developer of RNA therapeutics for the treatment of neurological disorders | $21M | 17 mo ago | 3 | — | — | — | 1 partnership |
| 33 | Invert Modern software for bioprocess development and scale-up | $21M | 23 mo ago | 19 | Martin Tromp Permin Co-Founder | — | — | — |
| 34 | Ossiform Developer of 3D printed resorbable bone implants | $21M | 44 mo ago | 11 11 → 16 (+45%) · sector median +71% | Morten O Andersen Co-Founder | — | — | — |
| 35 | Immudex Provider of immune monitoring reagents and services for research and clinical use | $19M | 16 mo ago | 39 39 → 46 (+18%) · sector median +71% | Patrik Dahlen Chief Executive Officer | — | — | — |
| 36 | Commit Biologics Developer of immunotherapies for the treatment of a variety of cancers | $17M | 16 mo ago | 8 | — | — | 4 patents Therapeutic antibodies and complement-engaging engineered proteins for cancer immunotherapy | 3 job openings |
| 37 | Flow Robotics Provider of an AI-based laboratory automation robot system for liquid handling | $17M | 48 mo ago | 28 | Andres Faina Co-Founder | — | 6 patents Automated laboratory tube handling and scanning robotics for high-throughput testing. | — |
| 38 | Neurescue Developer of catheter to manage blood flow from other organs to the heart and brain | $15M | 28 mo ago | 9 | Habib Frost Founder & CEO | — | — | — |
| 39 | Vivostat Provider of on-site preparation of fibrin sealants | $13M | 37 mo ago | 9 | — | — | 11 patents Surgical tissue sealants for ACL and GI anastomoses; blood sample processing devices. | — |
| 40 | Samplix ApS Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells | $13M | 38 mo ago | 26 26 → 31 (+19%) · sector median +71% | Marie Mikkelsen Co-founder & CTO | — | 65 patents Fluorinated surfactant microfluidics for droplet generation, sorting, and DNA enrichment | — |
| 41 | Biograil Provider of technology for oral delivery of biologics | $11M | 11 mo ago | 6 | Lars Christiansen Founder | — | — | — |
| 42 | Kvantify Provider of quantum computing solutions for businesses in industries such as finance, life sciences, and… | $11M | 3 mo ago | — | Allan Gronlund Co-Founder & CTO | — | — | 1 award |
| 43 | Hervolution Developer of immunotherapies for cancer treatment | $6M | 17 mo ago | 16 16 → 37 (+131%) · sector median +71% | — | — | — | — |
| 44 | Fuse Vectors Provider of scalable gene therapy manufacturing platform | $5M | 15 mo ago | 3 | Benjamin Blaha Chief Technology Officer | — | 2 patents In‑vitro production of parvovirus capsids for viral vector gene‑therapy manufacturing | — |
| 45 | Droplet IV Developer of an automatic flushing device for intravenous lines | $5M | 12 mo ago | 8 | Rasmus Falt Co-Founder | — | — | — |
| 46 | Aioss Provider of personalised health supplement brand | $3M | 18 mo ago | — | Theodor Barington Co-Founder | — | — | 5 launchs |
| 47 | VentriJect Provider of non-wearable device and app for monitoring cardiorespiratory fitness | $2M | 10 mo ago | 5 | — | — | — | — |
| 48 | Alcolase Developer of supplement for the management of alcohol intolerance | $2M | 1 mo ago | 4 | Mads Mikkelsen Co-Founder & CEO | — | — | — |
| 49 | ABH Optics Developer of lightweight eyeglass lenses | $1M | 22 mo ago | — | Henrik Bense-Petersen Co-Founder | — | — | — |
| 50 | BOOST Pharma Developer of stem cell therapies for Osteogenesis Imperfecta | $547K | 7 mo ago | 8 | Cecilia Gotherstrom Co-Founder | 3 signals Announcements | — | — |
Top 12 Life Sciences companies in Denmark
#1
Series C · Frederiksberg, Capital Region of Denmark · founded 2017 · 23 employees$113Mraised▾
Developer of antibody-drug conjugates for the treatment of cancer. The company's drug is developed to target specialized endocytic receptors that are uPARAP and endo180. It allows targeted therapy in cancer, including soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.
- Apr 2026Series C$75M
- Nov 2024Series B$135M
- May 2024Series A$17.4M
- Apr 2023Series A$33.9M
#2
Hemab 🦄Public · Copenhagen, Capital Region of Denmark · founded 2019 · 10 employees$190Mraised▾
Developer of preventative treatments for rare bleeding and thrombotic disorders. It develops novel therapies designed to modulate the body's clotting pathway, using antibodies to either stabilize or inhibit clotting factors. This approach addresses a significant unmet need for patients with less common disorders, offering prophylactic treatments and potential functional cures to prevent life-threatening complications. The company's pipeline includes several therapeutic candidates targeting various rare clotting disorders.
- Oct 2025Series C$157M
- Feb 2023Series B$135M
- Jul 2021Series A$15M
- Nov 2020Seed$3M
#3
Series B · Lyngby, Capital Region of Denmark · founded 2017 · 22 employees$43.6Mraised▾
Developer of biological solutions to reduce bacterial gastrointestinal infections. The company has developed a Virulence Inactivating protein and Ablacto for targeting specific pathogens to reduce the risk of gastrointestinal infections in animals and humans.
- Jan 2026Series B$35.1M
- Aug 2023Series A$33M
- Aug 2022Grant (prize money)$5M
- Apr 2021Seed$8.5M
#4
Seed · Copenhagen, Capital Region of Denmark · founded 2022$10.7Mraised▾
Kvantify is a company that provides off-the-shelf, sector-specific solutions for the financial services and life sciences industries. They use cutting-edge algorithms and quantum computing technology to address hard computational challenges. Kvantify aims to democratize access to advanced computing technology and help businesses contribute to a better future.
- Mar 2026Seed$8.1M
- Jul 2024Seed$10.7M
- Feb 2023Grant (prize money)$713K
- Grant (prize money)—
#5
Series B · Copenhagen, Capital Region of Denmark · founded 2011 · 48 employees$53.9Mraised▾
Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely. The company focuses on treating difficult conditions like multidrug-resistant infections, cystic fibrosis, IBD, and certain cancers by engineering the human microbiome.
- Aug 2025Series B$40.6M
- Dec 2024Venture Debt$21.1M
- Jan 2024Series B$11.9M
- Jun 2022Series A$8.4M
#6
Public · Hellerup, Capital Region of Denmark · founded 1994 · 35 employees$185Mraised▾
Developer of therapeutic vaccines against cancer and infectious diseases. The company has proprietary poxviral-based vaccine platform technologies, to develop medicines that address a wide variety of infectious diseases and cancers. The company has developed a pipeline for Smallpox, RSV, COVID-19 and Immuno-oncology.
- Jan 2025Grant (prize money)$1.5M
- Mar 2021Post IPO$183.4M
#7
Seed · Copenhagen, Capital Region of Denmark · founded 2020 · 4 employees$1.7Mraised▾
Developer of supplement for the management of alcohol intolerance. The company is developing a supplement an oral form, that can degrade ingested alcohol before it hits the bloodstream that aims to help people with alcohol intolerance without experiencing side effects like flushing, rapid heartbeat, and nausea.
- May 2026Seed$1.7M
#8
Series A · Copenhagen, Capital Region of Denmark · founded 2017$87.3Mraised▾
Developer of peptide-based therapies for obesity and cardiometabolic disorders. It offers optimized analogues of naturally occurring GIP receptor inhibitors to induce weight loss and treat obesity without common gastrointestinal side effects.
- Dec 2024Series A$84.1M
- May 2022Seed$503.4K
- Jun 2021Seed$1.6M
- Oct 2018Seed$1.2M
#9
Series A · Copenhagen, Capital Region of Denmark · founded 2009 · 39 employees$19Mraised▾
Provider of immune monitoring reagents and services for research and clinical use. It offers a portfolio of products, including dextramer reagents for flow cytometry and other applications, Klickmer reagents, and custom solutions. The products are used to detect and characterize antigen specific immune cells, supporting research in areas such as vaccine development, cell therapy, and infectious disease. It also provides services such as custom allele production and proficiency testing. Its offerings enable researchers and clinicians to gain a deeper understanding of the immune response in various contexts.It provides a range of products and services such as Dextramer and dcode MHC multimers for detailed immune profiling, clinical grade reagents, monomers and U- Load reagents, techincal and scientfic support, and more.
- Feb 2025Series A$290.6K
- Feb 2024Series A$305.1K
- Mar 2023Series A$245.5K
- Apr 2022Series A$249K
#10
Series B · Hedehusene, Capital Region of Denmark · founded 2019 · 6 employees$10.9Mraised▾
Provider of technology for oral delivery of biologics. The solution provided is BIONND provides a solution for the dosing of biologics in a standard oral capsule. The platform delivers biologics by the oral route in a standard capsule by directing the biologic drug molecule inside the intestinal wall for release to the body. With the release of the drug molecule inside the intestinal wall, the usual barriers are circumvented.
#11
Series A · Copenhagen, Capital Region of Denmark · founded 2022 · 8 employees$32.9Mraised▾
Provider of drug discovery platform to develop multiple therapeutics. The company utilizes novel macrocyclic chemistry and computational platforms for high-throughput drug discovery and develop drug candidates for challenging targets.
- Jan 2025Series A$92.8M
- Feb 2024Seed$32.9M
#12
Seed · Aarhus, Capital Region of Denmark · founded 2021 · 8 employees$17.2Mraised▾
Developer of immunotherapies for the treatment of a variety of cancers. The company combines expertise in antibody development and complement research to refine the BiCE technology and creates a new type of immunotherapy for the treatment of a variety of cancers.
- Jan 2025Seed$5.8M
- May 2024Seed$17.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Denmark
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 304 Denmark-affiliated papers.
- University of Copenhagen96
- Technical University of Denmark84
- Aarhus University56
- Novo Nordisk Foundation26
- Aalborg University19
- Messenger RNA1→4
- Food processing1→4
- Production (economics)1→5
- Agriculture1→5
- Antibiotic resistance2→4
Where biotechnology is researched across Denmark
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.